Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4098S | ISIN: US6963894026 | Ticker-Symbol: 7NS0
NASDAQ
05.09.25 | 17:16
0,610 US-Dollar
-1,69 % -0,011
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALISADE BIO INC Chart 1 Jahr
5-Tage-Chart
PALISADE BIO INC 5-Tage-Chart

Aktuelle News zur PALISADE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:18Palisade Bio receives Health Canada clearance for FSCD drug trial1
15:01PALISADE BIO, INC. - 8-K, Current Report1
14:48Palisade Bio, Inc.: Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)87First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated...
► Artikel lesen
25.08.Palisade Bio, Inc.: Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-21084
PALISADE BIO Aktie jetzt für 0€ handeln
15.08.Palisade Bio registers 8.9M shares for resale by selling stockholders3
11.08.PALISADE BIO, INC. - 10-Q, Quarterly Report3
07.08.Palisade Bio, Inc.: Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108189PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC)...
► Artikel lesen
31.07.Palisade Bio secures patent allowance in China for PALI-21081
31.07.Palisade Bio, Inc.: Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China2
24.07.Palisade Bio, Inc.: Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million6
09.07.Palisade Bio appoints Emil Chuang to board of directors3
09.07.Palisade Bio, Inc.: Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors1
09.07.PALISADE BIO, INC. - 8-K, Current Report2
27.05.Palisade Bio meldet positive Phase-1-Ergebnisse für neues Medikament2
27.05.Palisade Bio reports positive Phase 1 results for new drug1
27.05.PALISADE BIO, INC. - S-1, General form for registration of securities1
27.05.Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis212Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs...
► Artikel lesen
12.05.PALISADE BIO, INC. - 10-Q, Quarterly Report1
06.05.Palisade Bio's PALI-2108 shows promise in ulcerative colitis study1
02.05.PALISADE BIO, INC. - 8-K, Current Report2
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1